Form 4: Cryo-Cell Co-CEO Portnoy Boosts Stake
Statement of Changes in Beneficial Ownership
Cryo-Cell International's Chairman and Co-CEO, David Portnoy, increased his direct beneficial ownership of common stock through open market purchases totaling 15,424 shares.
Summary
- David Portnoy, Chairman, Co-CEO, and a 10% owner of Cryo-Cell International Inc. (CCEL), acquired 15,424 shares of common stock through open market purchases.
- The purchases occurred on September 16, 17, and 18, 2025, at weighted average prices ranging from $4.43 to $4.46 per share.
- Following these transactions, Portnoy's direct beneficial ownership increased to 827,344 shares.
- He also holds significant indirect ownership totaling 672,664 shares through entities like PartnerCommunity, Inc. (161,833 shares), uTIPu, Inc. (57,306 shares), Mayim Limited Partnership (59,027 shares), and various personal accounts (401K, IRA, Spouse, Custodian for son).
- Portnoy holds 530,000 stock options with various exercise prices, vesting schedules, and expiration dates, including 280,000 options that vest immediately if the common stock reaches $25.00 per share.
Sentiment
Score: 8
Explanation: The significant open market purchases by a high-ranking insider (Chairman, Co-CEO, 10% Owner) at current market prices demonstrate strong confidence in the company's future performance and valuation. This is a very positive signal for investors, indicating management believes the stock is undervalued or has significant upside potential.
Positives
- Significant insider buying by a key executive (Chairman, Co-CEO, 10% Owner) signals strong confidence in the company's future prospects and current valuation.
- The open market purchases at prevailing prices align management's financial interests directly with those of public shareholders, indicating a belief in potential upside.
- The increase in direct beneficial ownership strengthens David Portnoy's personal stake in the company's performance, providing a strong incentive for value creation.
Risks
- A substantial portion of stock options (280,000 shares) are performance-based, vesting only if the company's common stock reaches $25.00 per share, which is significantly above the recent purchase prices and introduces reliance on substantial stock price appreciation.
- Some existing stock options have exercise prices higher than the recent purchase prices, indicating that these options could be underwater if the stock price does not increase.
Future Outlook
The future outlook is closely tied to the vesting schedules of various stock options, with some options vesting over several years. A significant block of 280,000 options is performance-based, designed to vest immediately if the company's common stock reaches $25.00 per share during its seven-year term. This structure provides a strong long-term incentive for management to drive substantial share price appreciation.
Management Comments
- The open market purchases of company stock by the Chairman and Co-CEO serve as a strong implicit statement of confidence in the company's current valuation and future growth prospects.
Industry Context
NA
Related Party Transactions
- Indirect beneficial ownership through PartnerCommunity, Inc., uTIPu, Inc., and Mayim Limited Partnership are disclosed, where David Portnoy holds various leadership or ownership roles, indicating related party holdings.
Stakeholder Impact
- Shareholders: The insider buying provides a positive signal of management confidence, which could potentially lead to increased investor interest and support for the company's share price.
- Employees: May perceive increased management commitment and stability, potentially boosting morale and confidence in the company's direction.
Next Steps
- Monitoring the vesting of various stock options on their scheduled dates, including those from the 01/03/2023, 12/22/2023, and 01/21/2025 grants.
- Observing if the company's common stock reaches the $25.00 per share threshold, which would trigger immediate vesting for 280,000 stock options granted on 12/22/2021.
Key Dates
| Date | Description |
|---|---|
| 08/30/2019 | Grant date for 26,243 stock options with an exercise price of $7.53, expiring 08/30/2029. |
| 12/20/2019 | Grant date for 23,636 stock options with an exercise price of $7.28, expiring 12/20/2029. |
| 12/22/2021 | Grant date for 280,000 stock options with an exercise price of $12.27, expiring 12/22/2028, vesting immediately if stock reaches $25.00. |
| 12/23/2022 | Grant date for 50,000 stock options with an exercise price of $4.30, expiring 12/23/2027. |
| 01/03/2023 | Grant date for 50,000 stock options with an exercise price of $4.77, expiring 01/03/2028, with staggered vesting. |
| 12/22/2023 | Grant date for 50,000 stock options with an exercise price of $6.47, expiring 12/22/2028, with staggered vesting. |
| 01/02/2024 | Vesting date for 8,749 stock options from the 01/03/2023 grant. |
| 12/22/2024 | Vesting date for 1/3 of the 12/22/2023 stock options. |
| 01/21/2025 | Grant date for 50,000 stock options with an exercise price of $8.08, expiring 01/21/2030, with staggered vesting. |
| 01/02/2025 | Vesting date for 21,000 stock options from the 01/03/2023 grant. |
| 09/16/2025 | Acquisition of 6,449 common shares at a weighted average price of $4.46. |
| 09/17/2025 | Acquisition of 5,564 common shares at a weighted average price of $4.43. |
| 09/18/2025 | Acquisition of 3,411 common shares at a weighted average price of $4.46 and 1,751 indirect common shares at $4.49. |
| 01/02/2026 | Vesting date for 11,501 stock options from the 01/03/2023 grant. |
| 12/22/2025 | Vesting date for 1/3 of the 12/22/2023 stock options. |
| 01/21/2026 | Vesting date for 1/3 of the 01/21/2025 stock options. |
| 01/21/2027 | Vesting date for 1/3 of the 01/21/2025 stock options. |
| 12/23/2027 | Expiration date for 12/23/2022 stock options. |
| 01/03/2028 | Expiration date for 01/03/2023 stock options. |
| 12/22/2028 | Expiration date for 12/22/2021 and 12/22/2023 stock options. |
| 08/30/2029 | Expiration date for 08/30/2019 stock options. |
| 12/20/2029 | Expiration date for 12/20/2019 stock options. |
| 01/21/2030 | Expiration date for 01/21/2025 stock options. |
Recommendation
buyThe significant open market purchases by David Portnoy, who serves as Chairman, Co-CEO, and a 10% owner, represent a strong vote of confidence in Cryo-Cell International's future prospects. Insider buying, especially from a high-ranking executive, often signals that management believes the stock is undervalued or expects positive developments. This action aligns management's interests directly with shareholders and suggests potential upside, making it a compelling 'buy' signal for investors.
Keywords
Cryo-Cell International, CCEL, Insider Buying, Form 4, David Portnoy, Stock Purchase, Beneficial Ownership, SEC Filing, Biotechnology, Stem Cell Banking
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.